Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
– CEO Remi Barbier to Discuss Q1 2022 Clinical and Corporate Updates – – Stakeholders Are Invited to Submit Questions via Email – – Fireside Chat Will Be Open to The Public via Webcast – AUSTIN,...
-
AUSTIN, Texas, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced financial results for...
-
AUSTIN, Texas, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, announced today that the U.S. Food and...
-
New website (www.Rethink-ALZ.com) is intended to increase visibility and information for potential study participants.Rethink-ALZ.com connects patients with nearest participating clinical site.Phase 3...
-
Editor-in-Chief States: “After Careful Examination of These Original Material, Neuroscience [Journal] Found No Evidence of Manipulation of the Western Blot Data or Other Figures of This...
-
AUSTIN, Texas, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company, announced today it has initiated a second Phase 3 study of simufilam, the Company’s...
-
AUSTIN, Texas, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced financial results for...
-
AUSTIN, Texas, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) has been informed by the Journal of Neuroscience that there is no evidence of data manipulation in an article...
-
First Phase 3 Study is Initiated to Evaluate Safety and Efficacy of Simufilam Over 52 Weeks in 750 Patients with Alzheimer’s DiseaseA Second Phase 3 Study, Expected to Begin by Year End, Will Evaluate...
-
Cognition Scores Improved 3.2 Points on ADAS-Cog, Baseline to Month 12 (p<0.001) Two Independent Biostatisticians Analyzed Changes in ADAS-Cog Scores, Baseline to Month 12No Behavior Disorders on...